Eledon Pharmaceuticals (ELDN) Accumulated Expenses (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Accumulated Expenses data on file, last reported at $1.6 million in Q1 2026.

• Quarterly Accumulated Expenses rose 24.56% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 24.56% YoY) and the FY2025 annual result came in at $4.2 million, up 160.84% from the prior year.
• Accumulated Expenses slipped to $1.6 million in Q1 2026, from $4.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $9.3 million in Q3 2025 to a low of $814000.0 in Q1 2022.
• A 5-year average of $2.7 million and a median of $2.0 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 535.94% — and 2024, when it sank 56.78%.
• Tracing ELDN's Accumulated Expenses over 5 years: stood at $3.9 million in 2022, then tumbled by 34.94% to $2.5 million in 2023, then slumped by 37.09% to $1.6 million in 2024, then soared by 160.84% to $4.2 million in 2025, then sank by 60.66% to $1.6 million in 2026.
• The last three Accumulated Expenses figures came in at $1.6 million (Q1 2026), $4.2 million (Q4 2025), and $9.3 million (Q3 2025), per Business Quant data.